These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 310748)

  • 21. Procainamide: clinical pharmacology and efficacy against ventricular arrhythmias.
    Giardina EG
    Ann N Y Acad Sci; 1984; 432():177-88. PubMed ID: 6084435
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acetylprocainamide therapy in patients with previous procainamide-induced lupus syndrome.
    Kluger J; Drayer DE; Reidenberg MM; Lahita R
    Ann Intern Med; 1981 Jul; 95(1):18-23. PubMed ID: 6166229
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of N-acetylprocainamide.
    Atkinson AJ; Ruo TI
    Angiology; 1986 Dec; 37(12 Pt 2):959-67. PubMed ID: 2433970
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Arrhythmia control by selective lengthening of cardiac repolarization: role of N-acetylprocainamide, active metabolite of procainamide.
    Singh BN; Feld G; Nademanee K
    Angiology; 1986 Dec; 37(12 Pt 2):930-8. PubMed ID: 2433967
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of procainamide in chronic ambulatory peritoneal dialysis: report of a case.
    Kroboth PD; Mitchum K; Puschett JB
    Am J Kidney Dis; 1984 Jul; 4(1):78-9. PubMed ID: 6204527
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Correlation of the electrophysiological and antiarrhythmic properties of the N-acetyl metabolite of procainamide with plasma and tissue drug concentrations in the dog.
    Bagwell EE; Walle T; Drayer DE; Reidenbert MM; Pruett JK
    J Pharmacol Exp Ther; 1976 Apr; 197(1):38-48. PubMed ID: 1263131
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Simultaneous quantification of procainamide and N-acetylprocainamide with high-performance liquid chromatography.
    Carr K; Woosley RL; Oates JA
    J Chromatogr; 1976 Dec; 129():363-8. PubMed ID: 1002795
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The inotropic actions of N-acetylprocainamide: blockade and reversal by propranolol.
    Lertora JJ; King LW; Donkor KA
    Angiology; 1986 Dec; 37(12 Pt 2):939-49. PubMed ID: 2433968
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiarrhythmic potency of procainamide and N-acetylprocainamide in rabbits.
    Minchin RF; Ilett KF; Paterson JW
    Eur J Pharmacol; 1978 Jan; 47(1):51-6. PubMed ID: 618730
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term antiarrhythmic therapy with acetylprocainamide.
    Kluger J; Leech S; Reidenberg MM; Lloyd V; Drayer DE
    Am J Cardiol; 1981 Dec; 48(6):1124-32. PubMed ID: 6171156
    [TBL] [Abstract][Full Text] [Related]  

  • 31. N-acetylprocainamide induced changes in refractoriness and monophasic action potentials of the dog heart in situ.
    Amlie JP; Landmark K
    Cardiovasc Res; 1981 Mar; 15(3):159-63. PubMed ID: 6167356
    [TBL] [Abstract][Full Text] [Related]  

  • 32. N-acetylprocainamide's antiarrhythmic action in patients with ventricular tachycardia.
    Somberg J; Wynn J; Miura D; Torres V; Williams S; Keefe D
    Angiology; 1986 Dec; 37(12 Pt 2):972-81. PubMed ID: 2433972
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vivo and in vitro antiarrhythmic and arrhythmogenic effects of N-acetyl procainamide.
    Dangman KH; Hoffman BF
    J Pharmacol Exp Ther; 1981 Jun; 217(3):851-62. PubMed ID: 6164783
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative evaluation of procainamide and its main metabolite, N-acetylprocainamide, in the acute treatment of ventricular arrhythmias [proceedings].
    Karlsson E; Sonnhag C
    Br J Clin Pharmacol; 1977 Oct; 4(5):632P. PubMed ID: 911617
    [No Abstract]   [Full Text] [Related]  

  • 35. Acecainide (N-acetylprocainamide). A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cardiac arrhythmias.
    Harron DW; Brogden RN
    Drugs; 1990 May; 39(5):720-40. PubMed ID: 1693889
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Significance of acetylator phenotype in pharmacokinetics and adverse effects of procainamide.
    Ylitalo P; Ruosteenoja R; Leskinen O; Metsä-Ketelä T
    Eur J Clin Pharmacol; 1983; 25(6):791-5. PubMed ID: 6198178
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of N-acetylprocainamide in patients profiled with a stable isotope method.
    Atkinson AJ; Ruo TI; Piergies AA; Breiter HC; Connelly TJ; Sedek GS; Juan D; Hubler GL; Hsieh AM
    Clin Pharmacol Ther; 1989 Aug; 46(2):182-9. PubMed ID: 2474402
    [TBL] [Abstract][Full Text] [Related]  

  • 38. N-acetylprocainamide kinetics during intravenous infusions and subsequent oral doses in patients with coronary artery disease and ventricular arrhythmias.
    Ludden TM; Crawford MH; Kennedy GT
    Pharmacotherapy; 1985; 5(1):11-5. PubMed ID: 2580291
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hemodynamic effects of N-acetylprocainamide in heart disease.
    Crawford MH; Ludden TM; Kennedy GT; Sodums MT; O'Rourke RA; Amon KW
    Clin Pharmacol Ther; 1982 Apr; 31(4):459-65. PubMed ID: 6174263
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of age, renal function and heart failure on procainamide clearance and n-acetylprocainamide serum concentrations.
    Bauer LA; Black D; Gensler A; Sprinkle J
    Int J Clin Pharmacol Ther Toxicol; 1989 May; 27(5):213-6. PubMed ID: 2472362
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.